Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Other Non-Current Liabilities (2016 - 2021)

Protalix BioTherapeutics has reported Other Non-Current Liabilities over the past 8 years, most recently at $38000.0 for Q2 2021.

  • Quarterly results put Other Non-Current Liabilities at $38000.0 for Q2 2021, down 69.35% from a year ago — trailing twelve months through Jun 2021 was $38000.0 (down 69.35% YoY), and the annual figure for FY2020 was $51000.0, down 89.98%.
  • Other Non-Current Liabilities for Q2 2021 was $38000.0 at Protalix BioTherapeutics, up from $26000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for PLX hit a ceiling of $6.2 million in Q3 2018 and a floor of $26000.0 in Q1 2021.
  • Median Other Non-Current Liabilities over the past 5 years was $5.1 million (2017), compared with a mean of $2.9 million.
  • Biggest five-year swings in Other Non-Current Liabilities: rose 17.44% in 2017 and later tumbled 99.14% in 2020.
  • Protalix BioTherapeutics' Other Non-Current Liabilities stood at $5.1 million in 2017, then rose by 4.77% to $5.3 million in 2018, then crashed by 90.38% to $509000.0 in 2019, then plummeted by 89.98% to $51000.0 in 2020, then fell by 25.49% to $38000.0 in 2021.
  • The last three reported values for Other Non-Current Liabilities were $38000.0 (Q2 2021), $26000.0 (Q1 2021), and $51000.0 (Q4 2020) per Business Quant data.